Table 1 Demographic and Clinical Characteristics in Propensity Score Matched DOAC and Warfarin Cohorts
Warfarin Cohort (N = 3691) | Dabigatran Cohort (N = 3691) | Warfarin Cohort (N = 8226) | Rivaroxaban Cohort (N = 8226) | Warfarin Cohort (N = 7607) | Apixaban Cohort (N = 7607) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | N/Mean | %/SD | |
Age | 74.0 | 10.3 | 74.0 | 9.5 | 76.5 | 9.7 | 76.5 | 9.3 | 76.6 | 9.8 | 76.5 | 9.5 |
18–54 | 134 | 3.6% | 106 | 2.9% | 180 | 2.2% | 168 | 2.0% | 178 | 2.3% | 172 | 2.3% |
55–64 | 425 | 11.5% | 434 | 11.8% | 625 | 7.6% | 590 | 7.2% | 563 | 7.4% | 558 | 7.3% |
65–74 | 1244 | 33.7% | 1286 | 34.8% | 2278 | 27.7% | 2275 | 27.7% | 2057 | 27.0% | 2157 | 28.4% |
≥ 75 | 1888 | 51.2% | 1865 | 50.5% | 5143 | 62.5% | 5193 | 63.1% | 4809 | 63.2% | 4720 | 62.0% |
Gender | ||||||||||||
Male | 2240 | 60.7% | 2245 | 60.8% | 4812 | 58.5% | 4791 | 58.2% | 4430 | 58.2% | 4431 | 58.2% |
Female | 1451 | 39.3% | 1446 | 39.2% | 3414 | 41.5% | 3435 | 41.8% | 3177 | 41.8% | 3176 | 41.8% |
Geographic Region | ||||||||||||
Northeast | 270 | 7.3% | 282 | 7.6% | 807 | 9.8% | 788 | 9.6% | 644 | 8.5% | 632 | 8.3% |
North Central | 559 | 15.1% | 566 | 15.3% | 1409 | 17.1% | 1377 | 16.7% | 1191 | 15.7% | 1182 | 15.5% |
South | 1862 | 50.4% | 1865 | 50.5% | 3701 | 45.0% | 3709 | 45.1% | 3688 | 48.5% | 3672 | 48.3% |
West | 929 | 25.2% | 911 | 24.7% | 2138 | 26.0% | 2174 | 26.4% | 1933 | 25.4% | 1966 | 25.8% |
Other | 71 | 1.9% | 67 | 1.8% | 171 | 2.1% | 178 | 2.2% | 151 | 2.0% | 155 | 2.0% |
Baseline Comorbidity | ||||||||||||
Deyo-Charlson Comorbidity Index | 2.0 | 2.1 | 2.0 | 2.1 | 2.5 | 2.4 | 2.5 | 2.4 | 2.5 | 2.4 | 2.5 | 2.4 |
CHADS2 Score | 2.3 | 1.3 | 2.3 | 1.4 | 2.5 | 1.4 | 2.6 | 1.4 | 2.6 | 1.4 | 2.6 | 1.4 |
0 = low risk | 309 | 8.4% | 298 | 8.1% | 453 | 5.5% | 491 | 6.0% | 408 | 5.4% | 422 | 5.5% |
1 = moderate risk | 782 | 21.2% | 835 | 22.6% | 1408 | 17.1% | 1459 | 17.7% | 1294 | 17.0% | 1318 | 17.3% |
2 = high risk | 1209 | 32.8% | 1166 | 31.6% | 2528 | 30.7% | 2351 | 28.6% | 2360 | 31.0% | 2247 | 29.5% |
>2 = high risk | 1391 | 37.7% | 1392 | 37.7% | 3837 | 46.6% | 3925 | 47.7% | 3545 | 46.6% | 3620 | 47.6% |
CHADS2-VASc Score | 3.7 | 1.8 | 3.7 | 1.8 | 4.1 | 1.7 | 4.1 | 1.8 | 4.1 | 1.8 | 4.2 | 1.8 |
0 = low risk | 84 | 2.3% | 99 | 2.7% | 117 | 1.4% | 117 | 1.4% | 111 | 1.5% | 108 | 1.4% |
1 = moderate risk | 303 | 8.2% | 251 | 6.8% | 414 | 5.0% | 389 | 4.7% | 377 | 5.0% | 363 | 4.8% |
2 = high risk | 517 | 14.0% | 562 | 15.2% | 901 | 11.0% | 931 | 11.3% | 832 | 10.9% | 872 | 11.5% |
>2 = high risk | 2787 | 75.5% | 2779 | 75.3% | 6794 | 82.6% | 6789 | 82.5% | 6287 | 82.6% | 6264 | 82.3% |
HAS-BLED Score | 2.8 | 1.3 | 2.8 | 1.2 | 3.0 | 1.3 | 3.0 | 1.3 | 3.0 | 1.3 | 3.0 | 1.3 |
0 = low risk | 92 | 2.49% | 80 | 2.17% | 117 | 1.42% | 101 | 1.23% | 110 | 1.45% | 100 | 1.31% |
1–2 = moderate risk | 1544 | 41.8% | 1472 | 39.9% | 3007 | 36.6% | 2982 | 36.3% | 2737 | 36.0% | 2606 | 34.3% |
>2 = high risk | 2055 | 55.7% | 2139 | 58.0% | 5102 | 62.0% | 5143 | 62.5% | 4760 | 62.6% | 4901 | 64.4% |
Baseline Prior Bleed | 573 | 15.5% | 572 | 15.5% | 1611 | 19.6% | 1632 | 19.8% | 1484 | 19.5% | 1525 | 20.0% |
Baseline Prior Stroke | 354 | 9.6% | 341 | 9.2% | 1034 | 12.6% | 1028 | 12.5% | 907 | 11.9% | 931 | 12.2% |
Congestive Heart Failure | 749 | 20.3% | 752 | 20.4% | 2184 | 26.5% | 2207 | 26.8% | 2033 | 26.7% | 2052 | 27.0% |
Diabetes | 1211 | 32.8% | 1220 | 33.1% | 2853 | 34.7% | 2815 | 34.2% | 2593 | 34.1% | 2631 | 34.6% |
Hypertension | 3055 | 82.8% | 3059 | 82.9% | 6903 | 83.9% | 6881 | 83.6% | 6450 | 84.8% | 6469 | 85.0% |
Renal Disease | 625 | 16.9% | 640 | 17.3% | 1918 | 23.3% | 1943 | 23.6% | 1839 | 24.2% | 1852 | 24.3% |
Myocardial Infarction | 202 | 5.5% | 204 | 5.5% | 513 | 6.2% | 525 | 6.4% | 479 | 6.3% | 485 | 6.4% |
Dyspepsia or Stomach Discomfort | 645 | 17.5% | 652 | 17.7% | 1500 | 18.2% | 1492 | 18.1% | 1398 | 18.4% | 1404 | 18.5% |
Peripheral Vascular Disease | 1607 | 43.5% | 1615 | 43.8% | 4005 | 48.7% | 3986 | 48.5% | 3742 | 49.2% | 3755 | 49.4% |
Transient Ischemic Attack | 255 | 6.9% | 236 | 6.4% | 647 | 7.9% | 663 | 8.1% | 596 | 7.8% | 599 | 7.9% |
Coronary Artery Disease | 1347 | 36.5% | 1361 | 36.9% | 3331 | 40.5% | 3311 | 40.3% | 3126 | 41.1% | 3146 | 41.4% |
Baseline Medication Use | ||||||||||||
Angiotensin Converting Enzyme Inhibitor | 1285 | 34.8% | 1264 | 34.2% | 2938 | 35.7% | 2950 | 35.9% | 2714 | 35.7% | 2696 | 35.4% |
Amiodarone | 340 | 9.2% | 336 | 9.1% | 814 | 9.9% | 843 | 10.2% | 765 | 10.1% | 772 | 10.1% |
Angiotensin Receptor Blocker | 930 | 25.2% | 958 | 26.0% | 1993 | 24.2% | 1990 | 24.2% | 1921 | 25.3% | 1983 | 26.1% |
Beta Blockers | 2509 | 68.0% | 2540 | 68.8% | 5659 | 68.8% | 5702 | 69.3% | 5304 | 69.7% | 5286 | 69.5% |
H2-receptor Antagonist | 203 | 5.5% | 228 | 6.2% | 597 | 7.3% | 597 | 7.3% | 521 | 6.8% | 521 | 6.8% |
Proton Pump Inhibitor | 1324 | 35.9% | 1345 | 36.4% | 2972 | 36.1% | 2964 | 36.0% | 2817 | 37.0% | 2813 | 37.0% |
Anti-platelets | 836 | 22.6% | 818 | 22.2% | 1718 | 20.9% | 1705 | 20.7% | 1668 | 21.9% | 1740 | 22.9% |
Statins | 2188 | 59.3% | 2182 | 59.1% | 4897 | 59.5% | 4903 | 59.6% | 4572 | 60.1% | 4616 | 60.7% |
Dronedarone | 106 | 2.9% | 112 | 3.0% | 157 | 1.9% | 182 | 2.2% | 151 | 2.0% | 140 | 1.8% |
Calcium Channel Blockers | 1432 | 38.8% | 1457 | 39.5% | 3189 | 38.8% | 3156 | 38.4% | 3001 | 39.5% | 3000 | 39.4% |
Baseline Hospitalization | 1387 | 37.6% | 1368 | 37.1% | 3559 | 43.3% | 3612 | 43.9% | 3217 | 42.3% | 3237 | 42.6% |
Dosage on Index Date | ||||||||||||
Standard | 3125 | 84.7% | 5665 | 68.9% | 5714 | 75.1% | ||||||
Follow-up Time (in days) | ||||||||||||
minimum | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Q1 | 56 | 63 | 57 | 61 | 57 | 64 | ||||||
median | 148 | 163 | 150 | 177 | 153 | 161 | ||||||
Q3 | 358 | 436 | 354 | 411 | 359 | 333 | ||||||
maximum | 1001 | 999 | 1001 | 1002 | 1001 | 951 | ||||||